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In cancer patients, the ability to detect disseminated tumour cells in peripheral blood or bone marrow could improve prognosis and
consent both early detection of metastatic disease and monitoring of the efficacy of systemic therapy. These objectives remain elusive
mainly due to the lack of specific genetic markers for solid tumours. The use of surrogate tissue-specific markers can reduce the
specificity of the assays and give rise to a clinically unacceptable false-positive rate. Mammaglobin (MAM) and maspin are two putative
breast tissue-specific markers frequently used for detection of occult tumour cells in the peripheral blood, bone marrow and lymph
nodes of breast cancer patients. In this study, it was evaluated whether MAM and maspin gene expression may be induced in the
normal blood and bone marrow cells exposed to a panel of cytokines, including chemotactic factors (C5a, interleukin (IL)-8), LPS,
proinflammatory cytokines (TNF-a, IL-1b) and growth factors (IL-3, granulocyte-macrophage colony-stimulating factor, granulocyte
colony-stimulating factor). The experimental data show that all cytokines included in the panel, except for IL-8, were able to induce
maspin expression; on the contrary, MAM gene was never induced. These results suggest that MAM is more specific than maspin and
that the possible interference of cytokines should be taken into account in interpreting molecular assays for detection of isolated
tumour cells.
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In breast cancer patients, like some other epithelial tumours, the
presence of occult epithelial cells in the bone marrow or peripheral
blood has been assumed as a marker of systemic malignant disease
and, as a consequence, in the last two decades several immuno-
cytochemical and molecular methods for detection of disseminated
tumour cells have been developed with the aims of improving
prognosis, early detection of metastatic disease or of monitoring
the efficacy of systemic therapy.
Several studies suggest that these objectives can be achieved
with the current assays (Cote et al, 1991; Harbeck et al, 1994; Diel
et al, 1996; Smith et al, 2000; Terstappen et al, 2000; Gebauer et al,
2001; Jiang et al, 2002; Ozbas et al, 2003; Pantel et al, 2003) and in a
few of them the presence of disseminated tumour cells in bone
marrow or peripheral blood is recognised as an independent
prognostic factor (Diel et al, 1996; Braun et al, 2000; Stathopoulou
et al, 2002). However, the literature reports conflicting results and
the clinical value of these assays remains to be proven basically
because it is uncertain whether the published assays have enough
sensitivity, specificity and consistency to be reliably integrated
into prospective studies provided with adequate statistical power
to answer the most relevant clinical questions (Jiang et al, 2002;
Ozbas et al, 2003; Pantel et al, 2003). Accordingly, the most recent
TNM classification of breast cancer does not consider the lymph
nodes harbouring isolated tumour cells as positive, but it simply
suggests reporting this information, together with the method of
detection, in order to facilitate data collection (Singletary et al,
2002).
The molecular methods are mainly based on a qualitative
reverse transcriptase polymerase chain reaction (RT-PCR) identi-
fication of breast tissue-related mRNA sequences and show, in
experimental models, a sensitivity in the range of 1:10
6–10
7,
which is generally higher than immunocytochemistry (Smith et al,
2000; Jiang et al, 2002).
Unlike haematological tumours, the crucial limitation of the
molecular approach in breast cancer, as well as in other solid
tumours, is the lack of a tumour-specific genetic marker that has
induced the search for surrogate epithelial markers under the
assumption that they are not expressed in mesenchymal cells.
However, there are several factors such as pseudogenes, back-
ground gene expression and aberrant expression of epithelial
genes in mesenchymal cells under several physiological or
physiopathological conditions that can reduce the specificity of
the assay and give rise to an unacceptable incidence of false-
positive results (Zippelius et al, 1997; Jung et al, 1998, 1999; Ruud
et al, 1999; Kru ¨ger et al, 2001; Jiang et al, 2002). Mammaglobin
(MAM) and maspin are markers of major interest because some
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sevidence indicates that they have a stronger relationship with
breast tissue than several other epithelial markers such as cyto-
keratins, CEA and MUC-1 (Luppi et al, 1996; Zach et al, 1999;
Gru ¨newald et al, 2000; Ballestrero et al, 2001; Corradini et al, 2001;
Silva et al, 2002; Zehentner and Carter, 2004).
Human MAM is a small epithelial secretory protein detectable in
normal and pathological mammary tissue. It has a relative breast-
specific expression because it is also detectable in ovary,
endometrial and eccrine sweat gland tissues (Watson and Fleming,
1996; Gru ¨newald et al, 2002; Sjodin et al, 2003).
Maspin is a serine protease inhibitor with tumour-suppressive
activity due to its ability to inhibit metastatic tissue invasion,
angiogenesis and to sensitise tumour cells to apoptosis (Zou et al,
1994; Sheng et al, 1996; Zhang et al, 2000; Cher et al, 2003; Liu
et al, 2004). Maspin is also expressed in prostatic cells and other
tissues (Pemberton et al, 1997).
Although both MAM and maspin are frequently used for
detection of occult tumour cells in peripheral blood, bone marrow
and lymph nodes (Luppi et al, 1996; Zach et al, 1999; Gru ¨newald
et al, 2000; Ballestrero et al, 2001; Corradini et al, 2001; Silva et al,
2002; Zehentner and Carter, 2004), their specificity has been
questioned by some authors (Min et al, 1998; Merrie et al, 1999;
Lo ´pez-Guerrero et al, 1999; Suchy et al, 2000).
Taking into account that the ectopic transcription of epithelial
mRNA sequences is a decisive factor for the assay’s specificity, in
this article it has been evaluated whether certain biological factors
may induce MAM and/or maspin expression in mesenchimal cells.
Reverse transcriptase polymerase chain reaction was used to
evaluate the expression of MAM and maspin in normal blood and
bone marrow cells exposed to several cytokines, chemokines and
growth factors involved in the regulation of chemotaxis, inflam-
mation and haematopoiesis.
MATERIALS AND METHODS
Tissue samples, cell culture and cytokine stimulation
Samples from 10 non-neoplastic mammary tissue biopsies and
from 12 histologically confirmed breast cancer specimens (10
primary tumours and 2 liver metastases) were used as positive
control together with the tumour cell line MCF-7 expressing both
MAM and maspin genes (Luppi et al, 1996; Kru ¨ger et al, 2001). The
tissue specimens were frozen in liquid nitrogen within 60min from
surgical removal and kept frozen until tissue homogenisation prior
to RNA extraction.
Bone marrow specimens (3–5ml) from 35 healthy bone marrow
donors were used as negative controls to test the specificity of the
RT-PCR assays. Bone marrow specimens from patients with
malignant haematological disease, that is, 10 non-Hodgkin’s
lymphomas (NHL), five multiple myeloma (MM) and two acute
myeloid leukaemias (AML), were also tested for the MAM and
maspin transcript expression. Peripheral blood samples (15–
20ml) were also obtained from 35 healthy volunteers.
Polymorphonuclear (PMN) and mononuclear (Mono) cells
harvested from the bone marrow and peripheral blood of 10
healthy donors were used for in vitro cytokine stimulation
experiments.
Polymorphonuclear and Mono cells were isolated by means of
dextran (Solplex 70 Societa ` Italiana Farmaceutici, Verona, Italy)
sedimentation and subsequent centrifugation on a Ficoll-Hypaque
(F.H.Pharmacia, Uppsala, Sweden) density gradient. Contaminat-
ing erythrocytes were removed by hypotonic lysis. The cells were
washed three times with PBS and cultured at 5 10
6ml
 1 in RPMI
1640 with HEPES 25mM medium (EuroClone, UK) supplemented
with 10% FCS (ICN, Milano, Italy), 1% L-glutamine (200mM, Irvine
Scientific) and 1% antibiotics (penicillin 5000Uml
 1 and strepto-
mycin 5000mgml
 1, Gibco Lifethecnology, USA).
Human recombinant cytokines, growth factors and chemotactic
factors were added at the following concentration: INF-a ˜
100Uml
 1 (ICN, Milano, Italy), hr-tumour necrosis factor alfa
(TNF-a)1 0n gm l
 1 equal to 200Uml
 1 (ICN, Milano, Italy), hr-72
amino acids interleukin-8 (IL-8) 10Umg
 1 10
 7 M (Biosource
International, CA, USA), hr-interleukin-1b (IL-1) 10ngml
 1 equal
to 1000Uml
 1 (Biosource International, CA, USA), hr-interleukin-
3 (IL-3) 10ngml
 1 equal to 1000Uml
 1 (Biosource International,
CA, USA), hr-granulocyte-macrophage colony-stimulating factor
(GM-CSF) 10ngml
 1 (Genzyme, Cambrige, MA, USA), hr-
granulocyte colony-stimulating factor (G-CSF) 10ngml
 1 (Leno-
grastim, Italfarmaco, Italy), LPS Escherichia coli 011:B4 10mgml
 1
(Calbiochem-Novabiochem Corporation, Darmstadt Germany),
hr-Complement C5a 10
 7 M (Sigma Chemical Co, St Louis,
MO, USA).
Leukocytes were incubated with culture medium alone or
cytokines for 4, 8, 20, 72 and 96h. Each test was performed in
triplicate and each sample was considered positive if at least two of
the three tests were positive.
cDNA synthesis and RT-PCR for MAM and maspin
Total RNA was extracted using Trizol solution according to the
manufacturer’s instructions. In all, 1mg of total RNA was reverse
transcribed as described previously (Ballestrero et al, 2001).
Before amplification, all the cDNA samples were tested using a
standard protocol to amplify a gene-specific ABL sequence as
positive control (Ballestrero et al, 2001).
Mammaglobin RT-PCR assay was performed as follows. The
external primers used were MG-1 50-gAAgTTgCTgATggTCCT
CATgCTggC-30 and MG-2 50-CTCACCATACCCTgCAgTTCTgT
gAgC-30. The nested primers were MG-3 50-CTCCCAgCACTgCTAC
gCAggCTC-30 and MG-4 50-CACCTCAACATTgCTCAgAgTTTCAT
CCg-30 (Zach et al, 1999). The lengths of the primary and
reamplification products were 326 and 203bp, respectively. The
samples were subjected to 30 cycles of amplification (30s at 951C,
30s at 621C and 30s at 721C) and the second amplification was
carried out with 3ml of the first reaction product under the same
conditions as the first reaction.
Maspin nested PCR analysis was performed as reported
previously (Ballestrero et al, 2001).
In all, 10ml of the RT-PCR reactions were electrophoresed on a
2% agarose gel and stained with ethidium bromide for visualisa-
tion under UV light.
Statistical analysis
Confidence intervals were evaluated according to the Miettinen
(1970) test.
RESULTS
Detection, specificity and sensitivity of MAM and maspin
transcripts
Mammaglobin and maspin transcripts were detected by the nested
RT-PCR method in each positive control tissue, 10 non-neoplastic
mammary tissue samples, 10 primary BC and two liver metastases
and the mammary tumour cell line MCF-7.
To determine the specificity of the two RT-PCR assays,
specimens from both 35 bone marrow and 35 peripheral blood
normal donors were evaluated.
The MAM and maspin transcripts were negative in every
specimen, even after reamplification with nested primers. Thus,
test specificity was 100% with a 95% confidence interval ranging
from 90 to 100%, given these sample sizes.
In 40% of the samples from the bone marrow of patients with
haematological malignancies an ‘illegitimate’ maspin transcription
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swas observed, whereas MAM transcript was undetectable (Table 1
and Figure 1).
In order to assess the sensitivity of the assay, a mixing study was
performed using serial dilutions of the mammary carcinoma cell
line MCF-7 in peripheral blood Mono cells from healthy
volunteers. By using this approach, the nested primer RT-PCR
assay was able to detect one MCF-7 cell mixed with 10
7 normal
cells, for both MAM and maspin assays according to previously
published data (Luppi et al, 1996; Zach et al, 1999; Ballestrero et al,
2001) (data not shown).
Effect of chemotactic factors, cytokines and growth factors
on maspin and MAM gene expression
Bone marrow and peripheral leukocytes can be exposed in
different physiological and physiopathological conditions to
several cytokines that could induce expression of epithelial
markers in the absence of true contamination by epithelial cells.
To investigate this possibility, the expression of MAM and
maspin was evaluated in PMN and Mono cells exposed in vitro to a
panel of cytokines including chemotactic factors (C5a, IL-8), LPS,
pro-inflammatory cytokines (TNF-a, IL-1b) and growth factors
(IL-3, GM-CSF, G-CSF).
Mammaglobin and maspin were never expressed in control
samples where PMN and Mono cells were exposed to culture
medium alone. Otherwise, in experiments with cytokines, all
factors, with the exception of IL-8, were able to consistently induce
the expression of maspin gene in either bone marrow or peripheral
blood leukocytes (Table 2).
Both bone marrow PMN and Mono cells were sensitive to TNF-
a, LPS, C5a, IL-1 and IL-3. Granulocyte colony-stimulating factor
and INF-a ˜ were able to stimulate bone marrow PMN and Mono
cells, respectively.
The effects of cytokines on peripheral blood cells were more
selective.
LPS was able to induce maspin expression in PMN, C5a and
GM-CSF in Mono cells and IL-3 in both. The electrophoretic
analysis of one representative experiment is reported in Figure 2.
The kinetic of expression was different between PMN and Mono
cells; in fact maspin mRNA was detectable after 4h of incubation
in PMN and after 4 days in Mono cells. Interestingly, a longer
incubation period, that is, 8 and 20h, resulted in a downregulated
expression of maspin by PMN.
On the contrary, the expression of MAM was never induced in
PMN or Mono cells from either bone marrow or peripheral blood
even when exposition to cytokines was prolonged to 4 days.
DISCUSSION
The ability to detect the systemic disease in early-stage solid
tumours has, theoretically, a sound biological foundation and
could consent a rational clinical approach to the neoplastic
patients in terms of both prognosis and treatment planning.
In recent years the presence of occult epithelial cells in bone
marrow or peripheral blood has been assumed as a marker of
systemic malignant disease in spite of the current immunocyto-
chemical and molecular assays not giving information about the
clonogenic potential of detected tumour cells. This assumption is
apparently supported by some prospective studies suggesting that
the presence of isolated tumour cells in bone marrow or peripheral
blood is an independent prognostic factor (Diel et al, 1996; Braun
et al, 2000; Stathopoulou et al, 2002). However, the literature
reports conflicting results; so this subject is still under discussion
(Jiang et al, 2002; Ozbas et al, 2003; Pantel et al, 2003).
Compared with immunocytochemistry and Southern or North-
ern blotting methods, RT-PCR assays are relatively easy and
straightforward to perform, have a high sensitivity rate and are
suitable for analysing large numbers of cells. However, due to the
lack of tumour-specific genetic alterations, the RT-PCR-based
methods rely on the amplification of surrogate epithelial markers
that can give rise to false-positive results as a consequence of
several physiological or physiopathological factors (Zippelius et al,
Table 1 Detection of MAM and maspin mRNA in breast tissues, bone
marrow and peripheral blood control specimens
Sample source
No. of
samples
No. MAM
positive
No. maspin
positive
Non-neoplastic breast tissue 10 10 10
Primary breast carcinoma 10 10 10
Breast carcinoma metastases 2 2 2
Normal bone marrow 35 0 0
Normal peripheral blood 35 0 0
Pathologic bone marrow
a 17 0 7
aPathologic bone marrow included 10 NHL samples, five MM samples and two AML
samples.
Figure 1 Electrophoretic analysis in a 2% agarose gel of MAM and
maspin RT-PCR fragments obtained from different tissues. ABL: Abelson
transcript, this sequence was used as housekeeping gene; MCF7: positive
control; 1: non-neoplastic breast tissue; 2: primary breast carcinoma; 3:
breast carcinoma metastases; 4: normal bone marrow; 5: normal peripheral
blood; 6: pathologic bone marrow (NHL).
Table 2 Maspin expression induced by cytokines in bone marrow and peripheral blood cells from 10 healthy volunteers
Neg. control TNF-a LPS C5a IL-1 IL-3 IL-8 G-CSF GM-CSF c IFN
ABL + + + + + + + + + +
Bone marrow
PMN   ++ + + +   +   
Mono   ++ + + +      +
Peripheral blood
PMN    +   +       
Mono      +   +    +  
Positivity was defined as a minimum of seven out of 10 positive results.
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s1997; Jung et al, 1998; Jung et al, 1999; Ruud et al, 1999; Kru ¨ger
et al, 2001; Jiang et al, 2002).
In this study, we first compared RT-PCR detection of the two
breast cancer-specific markers maspin and MAM for sensitivity
and specificity. Both of the markers demonstrated similar
capacities to detect isolated tumour cells (about 1 out of 10
7),
and high specificity, not producing positive results in samples
obtained from healthy donors. However, subsequent testing of
maspin and MAM expression in leukocyte samples from patients
with haematological/inflammatory disorders indicated that maspin
mRNA was expressed in 40% of these samples whereas MAM was
never detectable.
Expression of epithelial markers in the bone marrow of patients
with nonepithelial tumours or inflammatory diseases has pre-
viously been reported (Zippelius et al, 1997; Zach et al, 1999;
Ballestrero et al, 2001; Kru ¨ger et al, 2001). Therefore, we evaluated
in normal blood cells the possibility of a cytokine-induced
expression of maspin and MAM.
In particular, we evaluated the effect on blood cells of a panel
of known leukocyte-activating cytokines including chemotactic
factors (C5a, IL-8), LPS, proinflammatory cytokines (TNF-a,
IL-1b) and growth factors (IL-3, GM-CSF, G-CSF).
All of the stimuli, except for IL-8, were able to induce maspin
mRNA expression in normal bone marrow PMN or Mono cells
(Table 2). Conversely, only LPS, C5a, IL-3, G-CSF and GM-CSF
induced maspin expression in peripheral blood cells. The reasons
for the different expression pattern of maspin between bone
marrow- and peripheral blood-derived cells are unclear, and may
involve a reduced sensitivity to cytokine-mediated gene induction
in terminally differentiated cells. Interestingly, while maspin
messenger became detectable in PMN after a few hours of
exposure to the activating stimuli, maspin expression in Mono
cells required a prolonged stimulation. On the contrary, the MAM
gene was never inducible by any of the cytokines used in the
stimulation experiments.
These results provide an explanation for the detection of maspin
mRNA in the peripheral blood and bone marrow samples of
patients with haematological diseases and inflammation. Besides,
they suggest that maspin should be considered an epithelial
marker with low specificity, whereas MAM may represent a more
specific marker for the detection of isolated tumour cells in
peripheral blood or bone marrow samples.
However, we found that MAM expression, similar to maspin
although to a lesser extent, is induced in normal leukocytes by
apheretic procedures (MAM and maspin were positive, respec-
tively, in 10 and 30% of apheretic products from normal donors
with negative peripheral blood before apheretic procedure, data
not shown). This observation is consistent with the previous
observations by Kru ¨ger et al (2001), who found MAM expression
in 7% of clinical samples of bone marrow and leukapheresis
products obtained from patients without epithelial cancer both in
basal condition and under stimulation by several cytokines,
including G- and GM-CSF, IL-3, IL-1 and INF-a ˜. The reason for
this effect is not understood, but since MAM is not inducible by
cytokines, at least in our in vitro model, other mechanisms such as
mechanical stress or reagents used during this procedure may play
a role in this context.
This observation suggests that the apheretic procedure per se
may be sufficient to upregulate in leukocytes markers other than
maspin, through a mechanism that is possibly not cytokine-
mediated. Thus, RT-PCR detection of isolated tumour cells on
apheretic products may be unreliable.
In conclusion, our data suggest that MAM is more specific than
maspin and should be considered a reliable epithelial marker for
the detection of disseminated tumour cells in patients’ samples,
probably with the exception of apheresis products. Furthermore,
these data suggest that several factors possibly responsible for an
ectopic gene expression should be taken into account in the
validation process of new molecular markers.
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